References
Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T, et al. New insight on the correlation of metabolic status on (18)F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04500-7.
Kasahara N, Kaira K, Bao P, Higuchi T, Arisaka Y, Erkhem-Ochir B, et al. Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma. Lung Cancer. 2018;119:71–7. https://doi.org/10.1016/j.lungcan.2018.03.001.
Kaira K, Shimizu K, Kitahara S, Yajima T, Atsumi J, Kosaka T, et al. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma. Eur J Cancer. 2018;101:181–90. https://doi.org/10.1016/j.ejca.2018.06.022.
Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016;43(11):1954–61. https://doi.org/10.1007/s00259-016-3425-2.
Levy EB, Fiel MI, Hamilton SR, Kleiner DE, McCall SJ, Schirmacher P, et al. State of the art: toward improving outcomes of lung and liver tumor biopsies in clinical trials-a multidisciplinary approach. J Clin Oncol. 2020:JCO1902322. https://doi.org/10.1200/JCO.19.02322.
Purandare NC, Kulkarni AV, Kulkarni SS, Roy D, Agrawal A, Shah S, et al. 18F-FDG PET/CT-directed biopsy: does it offer incremental benefit? Nucl Med Commun. 2013;34(3):203–10. https://doi.org/10.1097/MNM.0b013e32835c5a57.
Cho A, Hur J, Kang WJ, Cho HJ, Lee JH, Yun M, et al. Usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction. Eur Radiol. 2011;21(5):1077–87. https://doi.org/10.1007/s00330-010-2006-1.
Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016;27(1):147–53. https://doi.org/10.1093/annonc/mdv489.
Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–93. https://doi.org/10.1016/j.cell.2012.03.017.
Evangelista L. The prediction of response to immunotherapy in non-small cell lung cancer patients by 18F-FDG PET/CT. J Thorac Dis. 2019;11(11):E221–E3. https://doi.org/10.21037/jtd.2019.10.19.
Chen L, Zhou Y, Tang X, Yang C, Tian Y, Xie R, et al. EGFR mutation decreases FDG uptake in non-small cell lung cancer via the NOX4/ROS/GLUT1 axis. Int J Oncol. 2019;54(1):370–80. https://doi.org/10.3892/ijo.2018.4626.
Lv Z, Fan J, Xu J, Wu F, Huang Q, Guo M, et al. Value of (18)F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients. Eur J Nucl Med Mol Imaging. 2018;45(5):735–50. https://doi.org/10.1007/s00259-017-3885-z.
Sun X, Xiao Z, Chen G, Han Z, Liu Y, Zhang C, et al. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management. Sci Transl Med. 2018;10(431). https://doi.org/10.1126/scitranslmed.aan8840.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not describe any studies with human participants performed by any of the authors.
Additional information
This article is part of the Topical Collection on Letter to the Editor
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhao, L., Lin, Q. & Chen, H. Optimal image guidance for tumor biopsy in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 47, 2739–2740 (2020). https://doi.org/10.1007/s00259-020-04835-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-020-04835-6